An analysis of side-effect profiles of anti-seizure medications in persons with intellectual disability using the Matson Evaluation of Drug Side Effects (MEDS)

Journal of Intellectual and Developmental Disability

Volumn 26, Issue 4, 2001, Pages 283-295

  Matson, Johnny L ^a   Mayville, Erik A ^a   Bamburg, Jay W ^a   Eckholdt, C Scott ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b Pinecrest Developmental Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROATE SEMISODIUM;

ADULT; AKATHISIA; ARTICLE; CENTRAL NERVOUS SYSTEM; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; DRY SKIN; DYSKINESIA; DYSTONIA; ENDOCRINE FUNCTION; EPILEPSY; FEMALE; GENITAL SYSTEM FUNCTION; HUMAN; HYPERSALIVATION; INTELLECTUAL IMPAIRMENT; LETHARGY; MAJOR CLINICAL STUDY; MALE; SEIZURE; SIDE EFFECT; SLURRED SPEECH; TOOTH PAIN; VERTIGO;

EID: 0035702707     PISSN: 1326978X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13668250120087308     Document Type: Article

References (32)

1. Advokat, C. D., Mayville, E. A., & Matson, J. L. (2000). Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with intellectual disability. Research in Developmental Disabilities, 21, 75-84.
2. Aldenkamp, A. P., Alpherts, W. C., Diepman, L., van't Slot, B., Overweg, J., & Vermeulen, J. (1994). Cognitive side effects of phenytoin compared with carbamazepine in patients with localization-related epilepsy. Epilepsy Research, 19, 37-43.
3. Alvarez, N. (1998). Barbiturate in the treatment of epilepsy in people with intellectual disability. Journal of Intellectual Disability, 42, 16-23.
4. Alvarez, N., Besag, F., & Iivanainen, M. (1998a). Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability. Journal of Intellectual Disability Research, 42, 1-15.
5. Alvarez, N., Kern, R. A., Cain, N. N., Coulter, D. L., Iivanainen, M., & Plummer, A. T. (1998b). Antiepileptics. In S. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: the international consensus handbook. Columbus, OH: The Ohio State University Nisonger Center.
6. Aman, M. G., Paxton, J. W., Field, C. J., & Foote, S. E. (1986). Prevalence of toxic anticonvulsant concentrations in mentally retarded persons with epilepsy. American Journal of Mental Deficiency, 90, 643-650.
7. Aman, M. G., & Singh, N. N. (1988). Psychopharmacology of the developmental disabilities. New York: Springer.
8. American Psychiatric Association (1994). Diagnostic and statistical manual, 4th edn. Washington, DC: APA.
9. Besag, F. M. C. (1998). Lamotrigine in the treatment of epilepsy in people with intellectual disability. Journal of Intellectual Disability Research, 42, 50-56.
10. Brunet, L., Miranda, J., Farre, M., Berini, L., & Mendieta, C. (1996). Gingival enlargement induced by drugs. Drug Safety, 15, 219-231.
11. Brylewski, J. E., & Wiggs, L. (1998). A questionnaire survey of sleep and nighttime behavior in a community based sample of adults with intellectual disability. Journal of Intellectual Disability Research, 42, 154-162.
12. Burke, T. A., McKee, J. R., Pathak, D. S., Donahue, R. M. J., Parasuraman, T. V., & Batenhorst, A. S. (1999). Cost of epilepsy in an intermediate care facility for persons with intellectual disability. American Journal on Mental Retardation, 104, 148-157.
13. Connick, C. M., & Barsley, R. E. (1999). Dental neglect: definition and prevention in the Louisiana Developmental Centers for patients with MRDD. Special Care in Dentistry, 19, 123-127.
14. Cumella, S., Ransford, N., Lyons, J., & Burnham, H. (2000). Needs for oral care among people with intellectual disability not in contact with community dental services. Journal of Intellectual Disability Research, 44, 45-52.
15. Dodrill, C. B., & Temkin, N. R. (1989). Motor speed is a contaminating factor in evaluating the 'cognitive' effects of phenytoin. Epilepsia, 30, 453-457.
16. Friis, M. L. (1998). Valproate in the treatment of epilepsy in people with intellectual disability. Journal of Intellectual Disability Research, 42, 32-35.
17. Gaily, E., Granstrom, M. L., & Liukkonen, E. (1998). Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. Journal of Intellectual Disability Research, 42, 41-45.
18. Gallassi, R., Morreale, A., Di Sarro, R., Marra, M., Lugaresi, E., & Baruzzi, A. (1992). Cognitive effects of antiepileptic drug discontinuation. Epilepsia, 33 (Suppl. 6), S41-S44.
19. Heller, A. J., Chesterman, R. D., Crawford, P., Chadwick, D., Johnson, A. L., & Reynolds, E. H. (1995). Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomized comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry, 58, 44-50.
20. Iivanainen, M. (1998). Phenytoin: effective but insidious therapy in people with intellectual disability. Journal of Intellectual Disability Research, 42 (Suppl. 1), 24-31.
21. Iivanainen, M., & Savolainen, H. (1983). Side effects of phenobarbital and phenytoin during long-term treatment of epilepsy. Acta Neurologica Scandinavica, 68 (Suppl. 97), 49-67.
22. Isojarvi, J. T., Laatikainen, T. J., Pakarinen, A. J., Juntunen, K. T., & Myllyla, V. V. (1995). Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia,_36, 676-681.
23. Matson, J. L., & Baglio, C. S. (1998). Administrator's manual: Matson Evaluation of Drug Side Effects (MEDS). Baton Rouge, LA: Scientific Publishers.
24. Matson, J. L., Mayville, E. A., Bielecki, J., Barnes, W. H., Bamburg, J. W., & Baglio, C. S. (1998). Reliability of the Matson Evaluation of Drug Side Effecls (MEDS). Research in Developmental Disabilities, 20, 501-506.
25. Mattson, R. H. (1996). The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. Epilepsia, 37, 195.
26. Mattson, R. H., Cramer, J. A., Collins, J. F., Smith, D. B., Delgado-Escueta, A. V., Browne, T. R., Williamson, P. D., Treiman, D. M., McNamara, J. O., & McCuthen, C. B. (1985). Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine, 313, 145-151.
27. Mayville, E. A. (1998). A preliminary validity study of the Matson Evaluation of Drug Side Effects. Unpublished manuscript, Louisiana State University, Baton Rouge.
28. Meraw, S. J., & Sheridan, P. J. (1998). Medically induced gingival hyperplasia. Mayo Clinic Proceedings, 73, 1196-1199.
29. Mikati, M. A., Choueri, R., Khurana, D. S., Riviello, F., Helmers, S., & Holmes, G. (1998). Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. Journal of Intellectual Disability Research, 42, 57-62.
30. Ramsay, R. E., Wilder, B. J., Berger, J. R., & Bruni, J. (1983). A double blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology, 33, 904-910.
31. Trevisol-Bittencourt, P. C., da Silva, V. R., Molinari, M. A., & Troiano, A. R. (1999). Phenytoin as the first option in female epileptic patients? Arquivos de Neuro Psiquiatria,_57, 784-786.
32. Waisburg, H., & Alvarez, N. (1998). Carbamazepine in the treatment of epilepsy in people with intellectual disabilily. Journal of Intellectual Disability Research, 42, 36-40.